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Summary
The role of Fas ligand (FasL) in programmed cell death via interaction with its receptor Fas is well characterized. It has
been proposed that expression of FasL can confer immune privilege to some organs, allowing them to kill infiltrating
lymphocytes and inflammatory cells. However, a number of studies have shown that when tumors or transplants express
FasL, rejection often occurs as a consequence of proinflammatory functions of FasL. Here we demonstrate that FasL
elicits tumor immunity in a murine melanoma model with weak immunogenicity and low expression of major histocompatibil-
ity complex (MHC) class I. We show that protected mice recognize melanocyte differentiation self-antigens. Importantly,
tumor immunity is mediated by antibodies, as it can be transferred by serum from protected mice.
Introduction ports, some tumors were demonstrated to express FasL, and
this was proposed to be a mechanism used to escape an im-
mune response (O’Connell et al., 2001; Walker et al., 1998).Immune surveillance by both the innate and acquired arms of
the immune system plays a part in eliminating some transformed These findings are now the subject of much debate, as forced
expression of FasL on tumors or transgenic expression in organscells, although the scale of the protection afforded is debated
(Lanier, 2001). The frequent appearance of tumors in humans such as the pancreas often leads to a brisk neutrophil infiltration
and elimination of tumor or damage to the transgenic organillustrates the fact that many tumor cells are ignored, develop
mechanisms to escape, or at least tip the balance of an immune (Green and Ferguson, 2001).
We have used the B16F10 melanoma model to study theresponse, preventing their elimination. Fas ligand (FasL), a mem-
ber of the TNF family of proteins, is well characterized for its effects of FasL expression. This tumor is poorly immunogenic
and thus a good model to test strategies to enhance tumorrole in triggering apoptosis. Expression of FasL by activated
lymphocytes allows them to kill target cells expressing Fas immunity. We find that mice reject tumor cells transfected with
FasL and go on to develop tumor immunity. Unlike previous(Krammer, 2000). However, expression of FasL by these cells
is a two-edged sword, as activated lymphocytes themselves studies where immunity has been shown to be mediated by
CD8 lymphocytes, this immunity can be transferred by serum.express Fas and become susceptible to death. The Fas/FasL
axis thus limits an immune response and is a major player in Here we show that immune responses directed to melanocyte
differentiation antigens are indeed induced by FasL-expressingthe process of activation-induced cell death (Janssen et al.,
2000). tumor cells.
FasL expression is normally tightly restricted to activated
lymphocytes. However, it has been demonstrated that some Results
nonlymphoid tissues such as the eye and testis can express
FasL (Bellgrau et al., 1995; Griffith et al., 1995; Saas et al., Fas binding, and not the cytoplasmic chain of Fas,
mediates tumor rejection of FasL-expressing tumors1997). This has been proposed to underlie the immune privilege
enjoyed by these organs, in effect allowing them to kill infiltrating Counter to initial observations, a number of investigators have
now demonstrated that FasL transfected tumor cells are morelymphocytes (i.e., “kill the killers”). Shortly after these initial re-
S I G N I F I C A N C E
Tumors often evade immune responses despite expressing a number of potentially specific target molecules. Eliciting effective
responses to these is a major challenge in the field of tumor immunology. In this study, we show that the molecule Fas ligand behaves
as an adjuvant to generate an antitumor response. The immunity is mediated by tumor-specific antibodies, which can recognize
and lyse the tumor cell line. This demonstration of the involvement of FasL in the generation of antitumor antibodies may help in the
definition of new tumor antigens and in the design of better vaccines and therapies for melanoma.
CANCER CELL : OCTOBER 2002 · VOL. 2 · COPYRIGHT  2002 CELL PRESS 315
A R T I C L E
Figure 1. Rejection of FasL-expressing tumors
C57BL/6 mice were injected sc with 5  105 tumor cells. Cells were either untransfected B16WT (A) or stably transfected with full length FasL (B), full length
FasL with a mutation in the Fas binding site (FasLmut; C), truncated FasL (FasLtrunc D), or truncated FasL with no binding to Fas (FasLmut/trunc; E). Mip1-deficient
mice were given B16F10 transfected with full length FasL (F). Tumor growth was measured twice a week over a period of 5 weeks. Numbers represent
tumor-bearing mice/total.
efficiently rejected than FasL negative cell lines upon their injec- Mip1 deficient mice. Although the kinetics of tumor growth
were slightly slower for the B16FasL tumor versus the B16WTtion in vivo. The brisk tumor rejection seems to be mediated in
control, 7/10 mice injected with the B16FasL developed tumors,the main by infiltrating neutrophils. Although it seems clear that
suggesting a possible role for this neutrophil chemoattractantonce present, neutrophils can kill the tumor cells, little is known
in FasL-mediated tumor rejection (Figure 1F).about how the neutrophils are attracted in the first place. In a
first series of experiments, we established a model of FasL-
FasL-expressing melanoma induces tumor immunitymediated tumor rejection using the well-characterized murine
Of 123 mice vaccinated with a large dose of live B16FasL, 56%melanoma cell line B16F10. Stable cell lines expressing FasL
remained tumor-free (Table 1). When tumor-free vaccinatedwere established (B16FasL) and injected subcutaneously (sc)
mice were challenged with 5  105 B16WT, about half of theinto C57BL/6 mice.
69 mice (54%) rejected the second tumor. These results wereExamination of the site of injection revealed a small but
confirmed using two independent sublines of B16WT. For sub-clearly palpable swelling at the injected site up to 2 weeks after
sequent experiments, it was established that 107 irradiatedinjection. All 10 mice injected with the parental or wild-type
B16FasL could protect against a second tumor. This has theB16F10 (B16WT) developed tumors (Figure 1A), whereas 6 of
advantage of preventing the growth of the FasL-transfected9 rejected the FasL-expressing tumor (Figure 1B), confirming
tumors occurring in approximately 44% of mice given liveprevious studies using the B16 model and other murine tumor
B16FasL. All of the mice given irradiated B16FasL remainedmodels (Walker et al., 1998). This is probably due to a direct
tumor-free. 70% of these mice treated with irradiated B16FasLinteraction between Fas and FasL, since a mutant form of FasL
developed tumor immunity (n  90) and rejected tumor when(FasLmut), which contains a single point mutation in the extracel-
challenged with B16WT. As expected, irradiated B16WT did notlular domain that prevents Fas binding (Y218R) (Schneider et
al., 1997), abolished rejection, and tumors developed in all 10
mice (Figure 1C). This is consistent with previous observations
that FasL can activate neutrophils via Fas and that tumor rejec-
Table 1. The primary B16FasL is rejected and induces tumor immunity
tion is prevented in lpr mice that express a mutated nonsignaling
% mice tumor-freeFas (Hohlbaum et al., 2000; Shimizu et al., 2001). FasL has a
long and conserved cytoplasmic domain rich in proline residues Pretreatment/primary Secondary challenge
challenge (tumor type) Primary challengea with B16WT b(Hane et al., 1995; Suda et al., 1993), which could potentially
allow “reverse signaling” via FasL to the tumor cell, perhaps B16WT 6% N/A
5  105 live (n  34)causing the secretion of neutrophil chemoattractants. However,
B16FasL 56% 54%deletion of this domain (FasLtrunc Figures 1D and 1E) has no
5  105 live (n  123) (n  89)
influence on rejection, implying that it is the engagement of Fas, B16WT N/A 10%
rather than FasL reverse signaling, that leads to tumor rejection. 107 irradiated (n  50)
B16FasL N/A 70%Further support for role of neutrophils was obtained when
107 irradiated (n  90)tumors were injected into Mip1 deficient mice. Mip1 has
a Mice were either injected with 5  105 B16FasL or 107 irradiated B16FasL.previously been shown to act as a neutrophil chemoattractant
b Four to eight weeks later, tumor-free mice were challenged with 5  105(Alam et al., 1994; Lira et al., 1994). In agreement with these
B16F10 wild type tumor.observations, the ability to reject B16FasL was impaired in
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Table 2. CD8 lymphocytes do not confer protection in B16FasL-immunized
mice
Tumor-free mice
Experiment 1 Experiment 2
A: Isotype control depletion 4/4 5/5
CD4 depletion 4/4 6/6
CD8 depletion 4/4 6/6
B: Transfer of CD8 0/3 0/4
Transfer of CD4 and CD8 0/3 ND
Transfer of CD4-depleted splenocytes ND 0/4
A: Protected mice were treated twice with a pair of CD4 or CD8-deplet-
ing antibodies, then challenged the following day with 5 105 B16WT. Tumor
growth was monitored over a period of 5 months.
B: Lymphocytes were transferred from protected mice into naı¨ve recipients,
then challenged with 5  105 B16WT. Tumor growth was monitored over a
period of 8 weeks.
give rise to tumor immunity (Table 1), confirming results of other
studies (Dranoff et al., 1993). Similar results were obtained using
several different clones expressing FasL (data not shown).
Tumor immunity can be transferred by serum,
but not by CD4 or CD8 T cells
Mice were vaccinated with B16FasL and challenged with
B16WT tumor. Animals that rejected the tumor challenge were
then selected for further study and are subsequently referred
to here as “protected mice.” To determine which cells are critical
for tumor immunity, protected mice were depleted of CD4 or
CD8 T cells by administration of depleting antibodies in vivo.
Figure 2. Serum from protected mice transfers tumor immunity, and protec-Mice were then rechallenged with B16WT. Both CD4 and CD8
tion is dependent on CD4 T cellsT cells depleted mice were still able to reject the tumor (Table
A: 200 l of serum or 1.2 mg purified antibodies from protected mice was2). Similarly, the transfer of purified CD8 or CD8/CD4 lym-
transferred into naı¨ve C57BL/6 mice, and mice were challenged the follow-phocytes from protected mice did not prevent tumor growth.
ing day with 5  105 or 2  105 B16WT, respectively.
We also tested fresh ex vivo killing of B16WT or targets infected B: C57BL/6 mice were depleted of CD4 or CD8 T lymphocytes, injected with
with vaccinia viruses encoding melanocyte differentiation anti- 107 B16FasL, and then challenged with 5  105 B16F10.
gens. At a variety of effector target ratios, we detected no lytic
activity from splenocytes or purified CD8 lymphocytes (data
not shown).
cell-dependent manner, mice were depleted of CD4 or CD8 TThe lack of role of CD4 or CD8 T cells in mediating the
cells before vaccination with B16FasL. Depletion of CD8 didtumor immunity prompted us to test for the development of a
not affect the ability of protected mice to reject a secondaryhumoral antitumor response. Serum was collected from pro-
challenge with B16WT. However, the majority of protected micetected mice leaving a minimum period of 7 weeks after injection
depleted of CD4 developed tumor when challenged (Figure 2B).of B16FasL. This was pooled and then injected into naı¨ve mice,
This was confirmed in a second experiment where mice werewhich were subsequently challenged with 5  105 B16WT. 14/
thymectomised and treated with depleting antibodies for CD417 mice given serum were protected from challenge, whereas
and CD8 T cells. These profoundly T cell-deficient mice wereall of 17 given normal mouse serum developed tumor (Figure
injected with B16FasL and subsequently challenged with2A). Serum was still protective when obtained 6 months after
B16WT. Ten control, nondepleted mice rejected the tumor, whilevaccination, and serum from unvaccinated tumor-bearing mice
3/10 T cell-deficient mice rejected tumor. Thus, although medi-failed to protect (data not shown).
ated by antibody, the immune response to B16WT requires CD4To show that the tumor protection was mediated by anti-
T cell help.body, the immunoglobulin fraction of the serum from B16FasL-
treated or control mice was purified over a Protein L column,
known to bind a high proportion of murine IgG and IgM. 1.2 The serum from immunized mice reacts with melanoma
antigens and can trigger complement-mediatedmg of purified Ig was injected intravenously, followed by chal-
lenge with 2  105 B16WT. In this experiment, all four mice lysis of B16F10
B16WT (melanoma line from C57BL/6 mouse strain), K1735given control Ig developed tumor at day 26, while 3/4 of mice
given serum from protected mice remained tumor-free (Fig- (melanoma line from the C3H mouse strain), MC57 (methylchol-
anthrene-induced fibrosarcoma cell line from C57BL/6 mice),ure 2A).
To determine whether tumor immunity is established in a T 293T cells (human embryonal kidney fibroblast), HuTK-143B
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Figure 4. Protected mice show responses to melanocyte antigens
Mice were injected with vaccinia virus expressing the melanocyte differenti-
ation antigens gp100, Trp-1, Trp-2, Mart-1, or an irrelevant antigen, G2. Five
days later, viral titers were determined in ovaries.
A: Naı¨ve mice.
B: Protected mice.
This experiment was repeated twice with similar results. The dashed line
represents the limit of sensitivity of the assay.
Figure 3. Serum from protected mice surface stains B16F10 and includes the
isotypes IgG1, IgG2a, IgG2b
viruses expressing the melanocyte differentiation antigensTumor and primary cells were stained by indirect immunofluorescence using
the indicated secondary antibodies and analyzed by FACS. Dark shading- gp100, Trp-1, Trp-2, Melan-A/Mart-1, or an irrelevant antigen
control serum, open line-serum from protected mice. (G2, a glycoprotein from lymphocytic choriomeningitis virus)
(Overwijk et al., 1998). When injected into naı¨ve mice, these
viruses replicate, and this can be assayed by counting plaque-
forming units from ovaries infected with vaccinia virus. If the(TK) cells, (human osteoblastoma cell line) and thymocytes
mouse has preexisting immunity against melanocyte antigensfrom C57BL/6 mice were stained by indirect immunofluores-
carried by the virus, then replication will be inhibited and thecence using serum from protected, tumor-bearing, or control
mice. FACS analysis showed no staining with either control ovary plaque count reduced. Vaccinia titers measured in ovaries
serum or serum from tumor-bearing mice, whereas strong stain- were consistently high in control mice (Figure 4A). The majority
ing of B16WT was seen using the serum from protected mice of vaccinated mice infected with vac-gp100 cleared the virus
(Figure 3A). Serum also stained the other melanoma cell line or had reduced viral load (4 out of 6, Figure 4B), one vaccinated
K1735 (Figure 3F). There was a small amount of staining of mouse cleared vac-Trp-1, and viral titers to Mart-1/MelanA were
MC57 cells but not of 293T, TK, or thymocytes from C57BL/6 lowered in 2 mice by a factor of 103 as compared to controls
(Figures 3G–3J). All cells were cultured under the same condi- (Figure 4B). It is possible that B16FasL will also break tolerance
tions and the negative results on some of these indicate that to other tumor-associated and tumor-specific antigens ex-
antigens recognized by the polyclonal serum are not due to pressed by B16, and that the protection we observe may well
contaminants present in the culture medium. Seven weeks after be improved by such a polyspecific response. The observation
injection of B16FasL, antibodies were of the IgG1, IgG2a, and
that approximately 20% of mice exhibited depigmentation atIgG2b isotypes (Figures 3B–3D). No specific antibodies of the
the site of tumor inoculation (B16FasL) further supports theIgG3 (Figure 3E) or IgE or IgM isotypes were detected in the
findings that immune responses to melanocyte antigens wereserum of protected mice, although specific IgM antibodies were
induced in these mice.present in the earlier phase of the immune response (less than
seven weeks after injection of B16FasL).
B16FasL can mature dendritic cells
To gain more insight into how FasL expression might help primeTumor-immune mice react to melanocyte
tumor specific responses, we examined whether B16FasL coulddifferentiation antigens
mature dendritic cells (DC). Bone marrow-derived DCs wereIn a search for antigen-specific responses induced by vaccina-
tion with B16FasL, we took advantage of a panel of vaccinia cultured in vitro for 4 days and matured in the presence of
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irradiated B16WT, B16FasL, or soluble FasL-FLAG fusion pro-
tein. FasL was incubated either alone or crosslinked with anti-
FLAG mAb, then washed and added to allogeneic splenocytes
in a 4-day proliferation assay using tritiated thymidine. Activation
of splenocytes was improved significantly when DCs were ma-
tured in the presence of B16FasL or soluble crosslinked FasL
(Figures 5A and 5B). The maturation markers MHC class II,
CD83, and CD86 were also upregulated on DCs cultured with
FasL (Figure 5C).
Antibody-mediated tumor immunity is dependent
on Fc Receptors (FcRs)
As complement and Fc receptor mediate effector functions of
antibodies, we sought to determine the role of these two compo-
nents during the tumor rejection in the protected mice. In an in
vitro complement lysis assay, protected but not preimmune
serum gave significant lysis of B16WT (Figure 6A). Next, we
depleted complement in protected mice by repeated injections
(30 g/mouse each injection) of Cobra venom factor (CVF),
which depletes C3 (Shapiro et al., 2002). The mice were then
challenged with B16WT. In two separate experiments, 4/5 con-
trols and 7/8 CVF-treated mice rejected tumor.
To look for a role of antibody-dependent cell-mediated cyto-
toxicity (ADCC), we injected protected serum into Fc receptor
 chain-deficient mice (FcR/, which lack FcRI, FcRIII, and
FcRI) (Takai et al., 1994). Mice were given serum from protected
or control mice and then challenged with B16WT. All control
mice were protected from tumor when injected with protected
serum, whereas in the FcR/, the same serum no longer
provided protection (Figure 6B).
Discussion
FasL has an interesting pedigree in the field of tumor immunol-
ogy. Although Fas is expressed on a number of nonlymphoid
tissues, such as the liver, FasL expression is tightly regulated,
being found predominantly on activated lymphocytes. The role
of FasL in the immune system is well studied; it is one of the
mechanisms used by lymphocytes to kill targets expressing Fas
(Krammer, 2000), and it has also been suggested that Fas can
deliver an activating signal to T cells (Kennedy et al., 1999). In
addition, activated lymphocytes that coexpress Fas and FasL
Figure 5. Dendritic cells mature in the presence of B16FasLbecome susceptible to apoptosis (Janssen et al., 2000). The
importance of this for the control of peripheral T cell populations A and B: After culture in GM-CSF and IL-4, bone marrow dendritic cells from
C57BL/6 mice were matured overnight with anti-FLAG mAb as control, oris illustrated by the lymphoproliferation and autoimmunity devel-
FasL noncrosslinked or crosslinked with anti-FLAG (A), or irradiated B16WToped by humans or mice with mutations in Fas or FasL (Matiba
or B16FasL (B). BALB/c spleen cells were added to increasing numbers of
et al., 1997). dendritic cells, and proliferation was measured by 3H thymidine incorpora-
A few extralymphoid tissues including the brain, eye, and tion. Background proliferation in the absence of spleen cells was subtracted.
This experiment was repeated three times with similar results. * P 	 0.05,testis have been shown to express FasL. Expression of FasL
Student’s T test. Maturation markers of dendritic cells were stained by mAbat such sites is proposed to limit inflammation and confer immu-
after maturation with recombinant FasL overnight.noprivilege by allowing them to kill infiltrating lymphocytes ex-
C: Dark shading, anti-FLAG alone; open line, maturation with LPS or recombi-
pressing Fas (Bellgrau et al., 1995; Griffith et al., 1995; Saas et nant FasL crosslinked.
al., 1997). These observations incited much interest in several
fields, most notably transplantation and tumor immunology. Ini-
tial observations demonstrated expression of FasL on some
tumors, where it was proposed to allow them to escape the Ferguson, 2001). The expression of FasL in a number of in-
immune response. Following these observations, a number of stances provoked an intense neutrophil infiltrate (Allison et al.,
investigators tested the effects in tumor cells or transgenic or- 1997; Seino et al., 1997). Neutrophils express Fas and can be
gans overexpressing FasL. Often the results were disappointing activated by FasL to become cytotoxic (Chen et al., 1998). It is
(from the tumor’s standpoint); tumor cells or transgenic tissues believed that this neutrophil activation leads to tumor rejection,
and blocking with soluble Fas-Fc fusion protein reduced neutro-fared worse than their nontransfected counterparts (Green and
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Although the initial rejection of FasL-expressing tumor has
been studied extensively, little is known about how this affects
long-term tumor immunity. In a previous study, a CD8-de-
pendant protective response to lymphoma was induced by
treatment with tumor transfected with FasL (Seino et al., 1997;
Shimizu et al., 1999). In our experiments, depletion of CD8
cells had no effect, perhaps because B16F10 expresses low
levels of MHC class I. Similarly, depletion of CD4 cells from
protected animals did not reduce tumor rejection, although
transfer of CD4 cells and splenic B cells prevented tumor
growth in 2/4 animals while slowing growth in the other 2/4
(data not shown).
The B16F10 melanoma model has recently been shown to
belong to the type of tumors that are weakly immunogenic
because they grow as nodules “walled off” from the immune
system, and in addition it expresses low levels of MHC class I,
preventing activation of antitumor immunity mediated by CD8
lymphocytes (Ochsenbein et al., 2001). Thus, the B16F10 is a
particularly difficult tumor model in which to raise an adaptive
immune response, and might be representative of many human
tumors (Pardoll, 2001).
To our surprise, serum provided almost complete protection
against a secondary tumor challenge. The serum from protected
mice can recognize surface determinants on B16F10 and the
Figure 6. The serum mediated tumor immunity is FcR-dependent
unrelated melanoma cell line K1735. It is impossible at this stage
A: Serum from protected mice (PMS) was used in a complement lysis assay.
to say how broad the response is or which antigens on theNormal mouse serum (NMS) and wells without complement were included
melanoma are responsible for the protection afforded by serumas controls. This panel is representative of three separate experiments.
B: NMS or PMS was injected into FcR-deficient mice or age-matched transfer. We are planning to produce monoclonal antibodies
C57BL/6 controls, which were then challenged with 1  105 B16WT. from the protected animals to define some of these antigens.
However, our screen of melanocyte differentiation antigens ex-
pressed in recombinant vaccinia virus has identified some anti-
gens. gp100 and Trp-1 responses were detected in the pro-phil activation and killing of FasL-transfected tumor cells (Chen
tected mice. Trp-1 can be expressed at the cell surface, andet al., 1998). Our results using B16F10 transfected with a FasL
passive transfer of antibodies against Trp-1 has been shown tomutant which fails to bind Fas confirm these results.
induce rejection of melanoma in vivo (Hara et al., 1995; NaftzgerHowever, it is not entirely clear why FasL-transfected tumors
et al., 1996).induce such a brisk neutrophil infiltrate. Previous studies have
How FasL is able to elicit these responses is at present notsuggested a role for IL1
, as FasL-transfected fibrosarcoma
entirely clear. It seems likely that the effect is multifactorial. First,was not rejected in IL1
-deficient mice (Miwa et al., 1998). In
the recruitment and activation of neutrophils by FasL is likely aaddition, soluble FasL can also attract neutrophils, although
crucial event, as it not only allows early innate killing of the tumor,expression of a soluble form of FasL in tumor cells did not lead
but also leads to the secretion of proinflammatory cytokinesto their rejection, or to a neutrophil infiltrate (Hohlbaum et al.,
and further immune activation (Fuchs and Matzinger, 1996).2000; Ottonello et al., 1999; Seino et al., 1998). In this study,
Dendritic cells may be recruited by this milieu and induced towe tested rejection in mice deficient in MIP1. These mice were
take up tumor cells/antigen. Furthermore, FasL expressed onalso less efficient at rejecting the tumor, suggesting a possible
the tumor can help mature the DCs, leading to increased expres-role for MIP1 as a neutrophil chemoattractant in FasL-induced
sion of costimulatory molecules and consequent priming (Re-tumor rejection (Lee et al., 2000). Consistent with this finding
scigno et al., 2000) of CD4 T cells, which are clearly needed tois the recent demonstration that membrane-bound FasL leads
establish this immune response (Figure 2). The isotypes of theto increase of mRNA expression of MIP1 and other proin-
specific antibodies are IgG1, IgG2a, and IgG2b, indicating aflammatory mediators (Hohlbaum et al., 2001). As soluble FasL
mixed TH1/TH2 pattern. The use of other proinflammatory cyto-does not induce neutrophil infiltration, we examined the role of
kines expressed on tumor cells such as GM-CSF, B7-1, MHCthe cytoplasmic domain of FasL. This proline-rich domain of
class II, or cytokines may well work in a similar fashion byaround 70 amino acids is highly conserved between species
inducing effective DC maturation and crosspriming (Smyth etand can bind the src kinase fyn in vitro (Hane et al., 1995).
al., 2001). Recent evidence suggests that the innate antitumorPrevious studies have shown a role for FasL in the proliferation
response mediated by natural killer cells modulates the develop-of CD8 cells and also in cell cycle arrest of CD4 cells (Desbar-
ment of the adaptive immune response (Kelly et al., 2002). Simi-ats et al., 1998; Suzuki and Fink, 1998). Thus, it has been sug-
larly, it is possible that the innate immune response initiated bygested that FasL may deliver a “reverse signal” via the cyto-
FasL induces the humoral antitumor response found in thisplasmic domain. In our experiments, deletion of the cytoplasmic
study. Our experiments suggest a role for ADCC in tumor de-domain had no effect on the kinetics of tumor growth ex vivo
struction, as the tumor rejection was much reduced in FcR/(data not shown), and likewise had no effect on tumor rejection
in vivo. mice.
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CSF (200 U/ml), and medium was changed on days 2 and 3 by discardingSeveral monoclonal antibodies, such as anti-CD20 and anti-
adherent and loosely adherent cells. Using this protocol, murine DCs haveHER2, are already used in the treatment of cancer, and a larger
an immature phenotype on day 4. On day 4, soluble FasL-flag was addednumber are currently undergoing clinical trials (Houghton and
alone or crosslinked with 5 g/ml of anti-flag. Alternatively, DCs were incu-
Scheinberg, 2000). Antibodies are attractive for the treatment bated with irradiated (12,000 rad) B16F10 FasL overnight. Allogeneic prolifer-
of cancer, as they have many modes of action: blocking or ation was set up on day 5 by culturing 105 BALB/c spleen cells with 104
stimulation of a cell surface receptor, or cytotoxicity via comple- C57BL/6 dendritic cells that had been matured previously in the presence
or absence of FasL. Four days later, proliferation was assayed 3H-thymidinement or via ADCC. We show here that ADCC can account for
incorporation.some protection in this system. Finally, if inactive on these
counts, conjugated antibody can be used to deliver drugs or
Vaccinia assay
toxins to cancer cells. Single monoclonals will have their limita- Mice were infected intraperitoneally with 2  106 PFU of vaccinia expressing
tions, as they put a huge selective pressure on the tumor to different melanocyte antigens or control antigens. Both ovaries were har-
lose antigen expression, as do therapies inducing CD8 T cells, vested at 5 days, and the vaccinia titers were determined on TK monolayers
as described previously (Binder and Kundig, 1991).where loss of MHC class I will abolish responses against all
antigens. In order to produce a truly effective therapeutic tumor
Flow cytometry and complement lysis assayvaccine/immunotherapy in humans, it will probably be neces-
FACS staining with serum was performed at a concentration of 1/100, and
sary to induce responses against a number of antigens using control serum was obtained from untreated or nonimmunized mice with
multiple effector mechanisms. Our observations here may help tumors. Second layer antibodies included anti-mouse Ig (Dako), anti-IgG1,
in the definition of new cell surface tumor markers and may IgG2a, IgG2b, and IgG3 (Serotec). For the complement assay, B16F10 cells
were labeled for 90 min with 51Cr, washed thoroughly, and plated out atprovide an additional route to stimulate a broader antitumor
2.5  104 per well. Pooled serum from protected mice or normal mouseresponse.
serum was added at 1:5 dilution for 1 hr, washed off, then rabbit complement
(Low-Tox; Cedarlane, Canada) was added at 1:10 dilution for 3 hr. ChromiumExperimental procedures
release into the supernatant was determined by liquid scintillation.
Tumor cells and mice
AcknowledgmentsTumor cells were maintained in RPMI (Sigma) supplemented with 10% fetal
calf serum (FCS), L-glutamine, penicillin-streptomycin. FasL was cloned C-
The authors wish to acknowledge Prof. N. Restifo for the recombinant vac-terminal to GFP in pEGFP-C1 (Clontech). Mutants lacking the 72AA cyto-
cinia virus, Prof. I. Hart and Prof. R. Zinkernagel for B16F10, Prof. I. Fidlerplasmic chain and/or a point mutation that abolishes binding to Fas (Y218R)
for K1735, and R. Boone for FACS sorting. Thanks also to S. Sierro forwere created by PCR. B16F10 were transfected with DMRIE (Gibco) and
thymectomies, C. Hetherington for the excellent mouse facility, Prof. P.selected on 1.5 mg/ml G418; single cells were cloned by FACS and expres-
Morgan for providing the CVF, and Dr. C. Canova for help and advice. Thesion of FasL checked using Nok-1 (Pharmingen). The in vivo results are
research and personnel were supported by the Wellcome Trust, the MRC,representative of several different clones. 5  105 live or 1  107 irradiated
Cancer Research UK, and the Ludwig Institute.tumor cells were injected into C57BL/6 mice and tumor growth measured.
C57BL/6 mice were bred in our animal facility, and the FcR/ were obtained
from Taconic (Germantown, NY).
Received: April 4, 2002Depletion/transfer of CD4 and CD8 lymphocytes
Revised: August 20, 2002Pairs of rat IgG2b hybridomas secreting anti-CD4 (YTS191.1.2, YTS33.1.2)
and anti-CD8 (YTS169.4.2.1, YTS156.7.7) were used for depletions as de-
Referencesscribed previously (Qin et al., 1987). 100g of antibody was injected intraper-
itoneally 1 and 3 days prior to injection of 5  105 B16WT or 107 B16FasL.
Alam, R., Kumar, D., Anderson-Walters, D., and Forsythe, P.A. (1994). Macro-One day after the last injection, less than 1% of CD4 or CD8 were detected
phage inflammatory protein-1 alpha and monocyte chemoattractant peptide-in peripheral blood by FACS.
1 elicit immediate and late cutaneous reactions and activate murine mast
cells in vivo. J. Immunol. 152, 1298–1303.Transfer of CD4, CD8, B cells, and serum
CD4 and CD8 lymphocytes from spleen and inguinal lymph nodes were Allison, J., Georgiou, H.M., Strasser, A., and Vaux, D.L. (1997). Transgenic
purified by positive selection using directly conjugated beads to anti-CD4 expression of CD95 ligand on islet beta cells induces a granulocytic infiltra-
or anti-CD8 (Miltenyi Biotec), or using antibodies against CD4 (Pharmingen), tion but does not confer immune privilege upon islet allografts. Proc. Natl.
CD8 (Caltag), or B220 (Pharmingen) followed by anti-rat beads. Purity of Acad. Sci. USA 94, 3943–3947.
CD4 and CD8 was between 70% for CD8 and 95% for CD4 cells. 107
Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Duke, R.C.
CD4 and 5  106 CD8 per mouse were reinjected intravenously (i.v.) the day
(1995). A role for CD95 ligand in preventing graft rejection. Nature 377,
of purification. To obtain serum, blood was clotted at 37C for 1 hr, then 630–632.
kept at 4C for at least 1 hr, and spun at 20,000 g for 10 min. 200 l of
Binder, D., and Kundig, T.M. (1991). Antiviral protection by CD8 versusserum per mouse was reinjected i.v. Purification of the Ig fraction of serum
CD4 T cells. CD8 T cells correlating with cytotoxic activity in vitro arewas performed with a protein L column (Pierce) according to the manufactur-
more efficient in antivaccinia virus protection than CD4-dependent IL. J.er’s protocol. Protein L binds to the  light chain and allows purification of
Immunol. 146, 4301–4307.IgM and IgG and possibly other murine antibody isotypes (Svensson et al.,
1998). 1.2 mg of the Ig fraction was reinjected per mouse. For all transfer Chen, J.J., Sun, Y., and Nabel, G.J. (1998). Regulation of the proinflammatory
experiments, mice were challenged the day following transfer with 5  105 effects of Fas ligand (CD95L). Science 282, 1714–1717.
B16WT.
Desbarats, J., Duke, R.C., and Newell, M.K. (1998). Newly discovered role for
Fas ligand in the cell-cycle arrest of CD4 T cells. Nat. Med. 4, 1377–1382.Proliferation assay with dendritic cells
Murine dendritic cells were isolated from bone marrow. Erythrocytes were Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K.,
depleted with lysis buffer (Flowgen). Cells were cultured with RPMI 5% Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R.C. (1993). Vaccination
FCS (Hyclone) with 500 U/ml IL-4 (Peprotech) and 1000 U/ml GM-CSF with irradiated tumor cells engineered to secrete murine granulocyte-macro-
(Peprotech). Cultures were fed on day 2 and day 4 by aspirating off medium phage colony-stimulating factor stimulates potent, specific, and long-lasting
anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539–3543.and adding fresh medium. In some experiments, DCs were fed only on GM-
CANCER CELL : OCTOBER 2002 321
A R T I C L E
Fuchs, E.J., and Matzinger, P. (1996). Is cancer dangerous to the immune localization, second signals and cross priming in cytotoxic T-cell induction.
Nature 411, 1058–1064.system? Semin. Immunol. 8, 271–280.
Ottonello, L., Tortolina, G., Amelotti, M., and Dallegri, F. (1999). Soluble FasGreen, D.R., and Ferguson, T.A. (2001). The role of Fas ligand in immune
ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes.privilege. Nat. Rev. Mol. Cell Biol. 2, 917–924.
J. Immunol. 162, 3601–3606.
Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., and Ferguson, T.A.
Overwijk, W.W., Tsung, A., Irvine, K.R., Parkhurst, M.R., Goletz, T.J., Tsung,(1995). Fas ligand-induced apoptosis as a mechanism of immune privilege.
K., Carroll, M.W., Liu, C., Moss, B., Rosenberg, S.A., and Restifo, N.P. (1998).Science 270, 1189–1192.
gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-
Hane, M., Lowin, B., Peitsch, M., Becker, K., and Tschopp, J. (1995). Interac- reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J.
tion of peptides derived from the Fas ligand with the Fyn-SH3 domain. FEBS Exp. Med. 188, 277–286.
Lett. 373, 265–268.
Pardoll, D. (2001). T cells and tumours. Nature 411, 1010–1012.
Hara, I., Takechi, Y., and Houghton, A.N. (1995). Implicating a role for immune
Qin, S., Cobbold, S., Tighe, H., Benjamin, R., and Waldmann, H. (1987).recognition of self in tumor rejection: passive immunization against the brown
CD4 monoclonal antibody pairs for immunosuppression and tolerance in-locus protein. J. Exp. Med. 182, 1609–1614.
duction. Eur. J. Immunol. 17, 1159–1165.
Hohlbaum, A.M., Moe, S., and Marshak-Rothstein, A. (2000). Opposing ef-
Rescigno, M., Piguet, V., Valzasina, B., Lens, S., Zubler, R., French, L.,fects of transmembrane and soluble Fas ligand expression on inflammation
Kindler, V., Tschopp, J., and Ricciardi-Castagnoli, P. (2000). Fas engagementand tumor cell survival. J. Exp. Med. 191, 1209–1220.
induces the maturation of dendritic cells (DCs), the release of interleukin
Hohlbaum, A.M., Gregory, M.S., Ju, S.T., and Marshak-Rothstein, A. (2001). (IL)-1beta, and the production of interferon gamma in the absence of IL-12
Fas ligand engagement of resident peritoneal macrophages in vivo induces during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory
apoptosis and the production of neutrophil chemotactic factors. J. Immunol. responses. J. Exp. Med. 192, 1661–1668.
167, 6217–6224.
Saas, P., Walker, P.R., Hahne, M., Quiquerez, A.L., Schnuriger, V., Perrin,
Houghton, A.N., and Scheinberg, D.A. (2000). Monoclonal antibody thera- G., French, L., Van Meir, E.G., de Tribolet, N., Tschopp, J., and Dietrich, P.Y.
pies-a ‘constant’ threat to cancer. Nat. Med. 6, 373–374. (1997). Fas ligand expression by astrocytoma in vivo: maintaining immune
privilege in the brain? J. Clin. Invest. 99, 1173–1178.
Janssen, O., Sanzenbacher, R., and Kabelitz, D. (2000). Regulation of activa-
tion-induced cell death of mature T-lymphocyte populations. Cell Tissue Schneider, P., Bodmer, J.L., Holler, N., Mattmann, C., Scuderi, P., Terskikh,
A., Peitsch, M.C., and Tschopp, J. (1997). Characterization of Fas (Apo-1,Res. 301, 85–99.
CD95)-Fas ligand interaction. J. Biol. Chem. 272, 18827–18833.
Kelly, J.M., Darcy, P.K., Markby, J.L., Godfrey, D.I., Takeda, K., Yagita, H.,
Seino, K., Kayagaki, N., Okumura, K., and Yagita, H. (1997). Antitumor effectand Smyth, M.J. (2002). Induction of tumor-specific T cell memory by NK
of locally produced CD95 ligand. Nat. Med. 3, 165–170.cell-mediated tumor rejection. Nat. Immunol. 3, 83–90.
Seino, K., Iwabuchi, K., Kayagaki, N., Miyata, R., Nagaoka, I., Matsuzawa,Kennedy, N.J., Kataoka, T., Tschopp, J., and Budd, R.C. (1999). Caspase
A., Fukao, K., Yagita, H., and Okumura, K. (1998). Chemotactic activity ofactivation is required for T cell proliferation. J. Exp. Med. 190, 1891–1896.
soluble Fas ligand against phagocytes. J. Immunol. 161, 4484–4488.
Krammer, P.H. (2000). CD95s deadly mission in the immune system. Nature
Shapiro, S., Beenhouwer, D.O., Feldmesser, M., Taborda, C., Carroll, M.C.,407, 789–795.
Casadevall, A., and Scharff, M.D. (2002). Immunoglobulin G monoclonal
Lanier, L.L. (2001). A renaissance for the tumor immunosurveillance hypothe- antibodies to Cryptococcus neoformans protect mice deficient in comple-
sis. Nat. Med. 7, 1178–1180. ment component C3. Infect. Immun. 70, 2598–2604.
Lee, S.C., Brummet, M.E., Shahabuddin, S., Woodworth, T.G., Georas, S.N., Shimizu, M., Fontana, A., Takeda, Y., Yagita, H., Yoshimoto, T., and Matsu-
Leiferman, K.M., Gilman, S.C., Stellato, C., Gladue, R.P., Schleimer, R.P., zawa, A. (1999). Induction of antitumor immunity with Fas/APO-1 ligand
and Beck, L.A. (2000). Cutaneous injection of human subjects with macro- (CD95L)- transfected neuroblastoma neuro-2a cells. J. Immunol. 162, 7350–
phage inflammatory protein-1 alpha induces significant recruitment of neu- 7357.
trophils and monocytes. J. Immunol. 164, 3392–3401.
Shimizu, M., Fontana, A., Takeda, Y., Yoshimoto, T., Tsubura, A., and Matsu-
Lira, S.A., Zalamea, P., Heinrich, J.N., Fuentes, M.E., Carrasco, D., Lewin, zawa, A. (2001). Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with
A.C., Barton, D.S., Durham, S., and Bravo, R. (1994). Expression of the Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation
chemokine N51/KC in the thymus and epidermis of transgenic mice results by neutrophilic polymorphonuclear leukocytes associated with antitumor
in marked infiltration of a single class of inflammatory cells. J. Exp. Med. immunity. Cell. Immunol. 207, 41–48.
180, 2039–2048.
Smyth, M.J., Godfrey, D.I., and Trapani, J.A. (2001). A fresh look at tumor
immunosurveillance and immunotherapy. Nat. Immunol. 2, 293–299.Matiba, B., Mariani, S.M., and Krammer, P.H. (1997). The CD95 system and
the death of a lymphocyte. Semin. Immunol. 9, 59–68.
Suda, T., Takahashi, T., Golstein, P., and Nagata, S. (1993). Molecular cloning
and expression of the Fas ligand, a novel member of the tumor necrosisMiwa, K., Asano, M., Horai, R., Iwakura, Y., Nagata, S., and Suda, T. (1998).
factor family. Cell 75, 1169–1178.Caspase 1-independent IL-1beta release and inflammation induced by the
apoptosis inducer Fas ligand. Nat. Med. 4, 1287–1292. Suzuki, I., and Fink, P.J. (1998). Maximal proliferation of cytotoxic T lympho-
cytes requires reverse signaling through Fas ligand. J. Exp. Med. 187, 123–Naftzger, C., Takechi, Y., Kohda, H., Hara, I., Vijayasaradhi, S., and
128.Houghton, A.N. (1996). Immune response to a differentiation antigen induced
by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Svensson, H.G., Hoogenboom, H.R., and Sjobring, U. (1998). Protein LA, a
Acad. Sci. USA 93, 14809–14814. novel hybrid protein with unique single-chain Fv antibody- and Fab-binding
properties. Eur. J. Biochem. 258, 890–896.O’Connell, J., Houston, A., Bennett, M.W., O’Sullivan, G.C., and Shanahan,
F. (2001). Immune privilege or inflammation? Insights into the Fas ligand Takai, T., Li, M., Sylvestre, D., Clynes, R., and Ravetch, J. (1994). Fcer1g
enigma. Nat. Med. 7, 271–274. chain deletion results in pleiotropic effector cell defects. Cell 76, 519–529.
Ochsenbein, A.F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, Walker, P.R., Saas, P., and Dietrich, P.Y. (1998). Tumor expression of Fas
ligand (CD95L) and the consequences. Curr. Opin. Immunol. 10, 564–572.J., Hemmi, S., Hengartner, H., and Zinkernagel, R.M. (2001). Roles of tumour
322 CANCER CELL : OCTOBER 2002
